Abstract:Enzymatic asymmetric sulfoxidation using molecular oxygen as the oxidant is a promising green chemistry approach to chiral sulfoxide production. Despite the broad substrate spectrum of cyclohexanone monooxygenases (CHMOs), some unnatural substrates with bulky functional groups, such as the pharmaceutically relevant omeprazole sulfide, cannot be effectively accepted by CHMOs. Herein, we describe a set of variants derived from an Acinetobacter calcoaceticus CHMO (AcCHMO), whose active sites adjacent to the substrate tunnel were altered to shift the substrate specificity from cyclohexanone monooxygenation toward omeprazole sulfide sulfoxidation. We performed homologous modeling and molecular docking to identify key residues that might affect the substrate specificity. Two libraries of residues lining the active center of AcCHMO were then constructed and screened by an effective halo-based selection method using the solubility difference between the substrate (omeprazole sulfide) and product (esomeprazole). Functional evaluation of the resultant variants showed that the substrate specificity of AcCHMO was markedly altered from the small natural substrate (cyclohexanone) toward the desired bulky substrate (omeprazole sulfide) despite the extremely poor activity detected even for the best variant, M2 (0.61 U/g(prot)). The crystal structure of M2 complexed with a flavin adenine dinucleotide (FAD) prosthetic group was determined, which provided insight into the altered substrate specificity. To improve the activity of enzyme M2 toward pharmaceutical precursor omeprazole sulfide, we performed both local and global protein engineering among the two CASTing libraries surrounding FAD(+) and NADP(+) prosthetic groups and an error-prone PCR library of the full-length AcCHMO. As a result, variant M6 was obtained, giving a 50-fold higher activity compared to M2. This structure-guided protein engineering of AcCHMO provided a promising candidate for converting omeprazole sulfide into (S)-omeprazole using a green biocatalytic method.

Novel process for omeprazole synthesis

Improvement on Synthesis of 2-Chloromethyl-3,5-dimethyl-4-nitropyridine Hydrochloride

Synthesis of 2-mercapto-5-methoxyimidazo[4,5-b] pyridine

Improved Synthetic Approach to Tenatoprazole

New Synthetic Method of 2-Amino-3-methylpyridine

Synthesis technology of 3-n-propyl-2, 4-dihydroxyacetophenone

Synthesis of 3-Nitropyrazole

Synthesis of 3-Aminopyrrolidine and its N-alkylating Derivatives

Synthesis of 1-{6-(2-methylbenzoyl)- N -ethylcarbazole-3-yl}-ethane-1-one oxime O -acetate

Green Route to Synthesize Oxime

A New Method for the Synthesis of 4-Methoxyl-2,3,5-trimethylpyridine

Enzymatic Preparation Of The Chiral (S)-Sulfoxide Drug Esomeprazole At Pilot-Scale Levels

Rational design on loop regions for precisely regulating flexibility of catalytic center to mitigate overoxidation of prazole sulfides by Baeyer-Villiger monooxygenase

Engineering of Cyclohexanone Monooxygenase for the Enantioselective Synthesis of (S)-Omeprazole

New Synthesis Process for the Synthesis of Ezetimibe

Catalytic Asymmetric Synthesis of Esomeprazole by a Titanium Complex with a Hexa-aza-triphenolic Macrocycle Ligand

[Improved method of fluvoxamine synthesis].

Scalable Process of Spiro(cyclopropane)oxazepane Pyridine Carboxylic Acid Through Kulinkovich, Mitsunobu, and Pd-Catalyzed Intramolecular C–N Coupling

Continuous Flow Synthesis of Esomeprazole via Asymmetric Sulfoxidation

Acid-induced Atypical Spontaneous Conversion of 5-Amino-2,6-dioxooctahydro-1h-pyrrolo[2,1-d][1,5]oxazocine into 4-(Hydroxymethyl)-2,5-dioxooctahydro-1h-pyrrolo[1,2-d][1,4]diazepine

Synthesis of Novel Organic Intermediate Substituted Pyrazole Ethyl Formate and Pyrazolecarboxylic Acid